Medical Doctor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

William Han

Pulmonary Disease Baltimore, MD Medical Doctor

NPI 1558325316 CMS profile 70263

2700 Quarry Lake Dr, Suite 220, Baltimore, MD 21209

Open in the dashboard

General payments

$2,409

135 records reported · program years 2019–2021

Research payments

$0

Paid to them · None reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Through program year 2021, William Han of Baltimore, MD is reported in the CMS Open Payments database as having received $2,409 across 135 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 55th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $721 41
2020 General $707 34
2019 General $981 60

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Han
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to William Han were reported at $0. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year William Han Pulmonary Disease median Middle half National median
2019 $981 $377 $109–$1,340 $163
2020 $707 $230 $56–$907 $114
2021 $721 $269 $68–$1,072 $132
2022 $0 $390 $100–$1,457 $149
2023 $0 $419 $114–$1,659 $160
2024 $0 $476 $123–$1,818 $164
2025 $0 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. GlaxoSmithKline, LLC. $739 40 payments
  2. AstraZeneca Pharmaceuticals LP $563 37 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $324 19 payments
  4. Insmed, Inc. $134 9 payments
  5. Veran Medical Technologies, Inc. $104 1 payment
  6. Genentech USA, Inc. $69 3 payments
  7. Grifols USA, LLC $62 3 payments
  8. Actelion Pharmaceuticals US, Inc. $59 2 payments
  9. Genzyme Corporation $43 3 payments
  10. Regeneron Healthcare Solutions, Inc. $39 2 payments
  11. Other $273 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Food and Beverage $2,352 131 payments
  2. Education $56 4 payments
Products named General payments · program years 2019–2021
  1. TRELEGY ELLIPTA $304 15 payments
  2. NUCALA $196 11 payments
  3. BREZTRI $147 10 payments
  4. BEVESPI AEROSPHERE $138 10 payments
  5. Arikayce $118 8 payments
  6. Spin $104 1 payment
  7. STIOLTO RESPIMAT $102 6 payments
  8. FASENRA $92 5 payments
  9. ANORO ELLIPTA $86 5 payments
  10. SYMBICORT $83 5 payments
  11. Other $1,138 65 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$39,722

Medicare's payments for the services billed

Medicare patients

140

Average age 73

Services billed

291

77 women, 63 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Ischemic heart disease 51%
Chronic kidney disease 49%
COPD 48%
Heart failure 47%
Depression 45%
Diabetes 44%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

135 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record